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ABSTRACT We sought to describe the population pharmacokinetics of tigecycline
in critically ill patients and to determine optimized dosing regimens of tigecycline
for different bacterial infections. This prospective study included 10 critically ill pa-
tients given a standard dose of tigecycline. Blood samples were collected during one
dosing interval and were analyzed using validated chromatography. Population
pharmacokinetics and Monte Carlo dosing simulations were undertaken using Pmet-
rics. Three target exposures, expressed as ratios of the 24-h area under the curve to
MICs (AUC0–24/MIC), were evaluated (17.9 for skin infections, 6.96 for intra-
abdominal infections, 4.5 for hospital-acquired pneumonia). The median age, total
body weight, and body mass index (BMI) were 67 years, 69.1 kg, and 24.7 kg/m2, re-
spectively. A two-compartment linear model best described the time course of tige-
cycline concentrations. The parameter estimates (expressed as means  standard
deviations [SD]) from the ﬁnal model were as follows: clearance (CL), 7.50  1.11 li-
ters/h; volume in the central compartment, 72.50  21.18 liters; rate constant for
tigecycline distribution from the central to the peripheral compartment, 0.31  0.16
h1; and rate constant for tigecycline distribution from the peripheral to the central
compartment, 0.29  0.30 h1. A larger BMI was associated with increased CL of
tigecycline. Licensed doses were found to be sufﬁcient for Enterobacter cloacae, Esch-
erichia coli, Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus for
an AUC0–24/MIC target of 4.5 or 6.96. For a therapeutic target of 17.9, an increased
tigecycline dose is required, especially for patients with higher BMI. The dosing re-
quirements of tigecycline differ with the indication, with pathogen susceptibility,
and potentially with patient BMI.
KEYWORDS tigecycline, population pharmacokinetics, critically ill patients, severe
infections
Critically ill patients are at high risk of developing severe infections, resulting inprolonged hospital stays, higher treatment costs, and increased mortality. The
choice of appropriate antimicrobial therapy can be limited by the high rates of bacterial
resistance. Increased knowledge of antimicrobial pharmacokinetics can guide dose
optimization.
Tigecycline, the ﬁrst member of the glycylcycline class of antimicrobial agents, was
approved by the U.S. Food and Drug Administration (FDA) for the treatment of
complicated intra-abdominal infections (cIAI), complicated skin and skin structure
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infections (cSSSI), and community-acquired pneumonia (CAP) (1). Given its expanded
spectrum of in vitro antibacterial activity, tigecycline is also considered an agent
suitable for difﬁcult-to-treat infections in critically ill patients, although published data
on its pharmacokinetics in this population are very limited.
The FDA issued a black box warning on the increased risk of mortality with
tigecycline treatment for hospital-acquired pneumonia (HAP) and especially ventilator-
associated pneumonia (2). After further analysis of the available trials, Freire et al.
postulated that suboptimal tigecycline dosing was associated with an increased risk of
death (3). As such, several clinical studies have evaluated the efﬁcacy of increasing
tigecycline dosing regimens (4, 5). For critically ill patients, high-dose tigecycline may
be a desirable treatment strategy, although the appropriateness of a ﬁxed high dose
has not been determined, and it is unlikely to be appropriate given the wide range of
patients and indications for which it may be used.
Early efﬁcacy studies with animal models indicated that the ratio of the 24-h area
under the curve to the MIC of the pathogen (AUC0–24/MIC) was the preferred
pharmacokinetic/pharmacodynamic (PK/PD) index for tigecycline (6). However, the
speciﬁc PK/PD target differs depending on the type of infection. Various exposure-
response analyses have now been performed for tigecycline. Using a classiﬁcation
and regression tree approach, investigators have identiﬁed AUC0–24/MIC break-
points of 17.9 in the treatment of cSSSI, 6.96 for cIAI, and 4.5 for HAP (7–9).
However, which dose is required to achieve these targets in critically ill patients has
not been studied in detail.
The aims of this study were to describe the population pharmacokinetics (pop-PK)
of tigecycline in critically ill patients with severe infections, identify the patient factors
inﬂuencing pharmacokinetics, and utilize the resultant model to describe optimized
tigecycline dosage regimens for different bacterial infections.
RESULTS
Demographic data. The characteristics of the 10 critically ill patients with severe
infections included in this study are provided in Table 1. No severe hepatic insufﬁciency
was observed in the study. The infections were pulmonary (n  6), cIAI (n  1), cSSSI
(n  1), and multiple infections (pulmonary plus urinary tract infection; cSSSI plus
urinary tract infection) (n  2). Microbiological samples for one Staphylococcus aureus,
one Stenotrophomonas maltophilia, two Escherichia coli, two Pseudomonas aeruginosa,
TABLE 1 Demographic characteristics of 10 critically ill patients treated with tigecycline
for severe infections
Descriptive dataa
No. of patients or median
value (IQR)b
Female/male 4/6
Age (yr) 64 (36.5–73)
Weight (kg) 69.1 (59.7–70.8)
BMI (kg/m2) 24.7 (24.3–25.6)
APACHE II score at admission 20 (13–22)
Length of hospital stay (days) 24 (13–40.5)
Creatinine concn at admission (mg/dl) 0.7 (0.6–1.85)
Albumin concn at admission (g/dl) 2.8 (2.7–2.9)
Comorbid conditions
AKI 1
Hypertension 5
CRRT 2
COPD 2
MODS 2
Chronic renal failure 1
Diabetes mellitus 2
aAPACHE II score, Acute Physiology and Chronic Health Evaluation II score; AKI, acute kidney injury as
deﬁned per RIFLE criteria; CRRT, continuous renal replacement therapy; COPD, chronic obstructive
pulmonary diseases; MODS, multiple organ dysfunction syndrome.
bIQR, interquartile range.
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two Enterococcus faecalis, two Klebsiella pneumoniae, three Enterococcus faecium, and
four Acinetobacter baumannii strains were isolated from these patients.
Tigecycline pharmacokinetics. A two-compartment linear model adequately de-
scribed the time course of serum tigecycline concentrations. The goodness-of-ﬁt plots
of the model were considered acceptable, and the parameter estimates (given as
means and standard deviations [SD]) from the ﬁnal covariate model are shown in Table
2. Plots of the observed versus population-predicted concentrations and individual-
predicted concentrations are shown in Fig. 1. The r2, bias, and imprecision values for
prediction were 0.733, 0.391 mg/liter, and 4.54 mg2/liter2 for the population predictive
model and 0.944, 0.0768 mg/liter, and 0.975 mg2/liter2 for the posterior Bayesian
prediction, respectively. In the ﬁnal model, only body mass index (BMI) was supported
as a covariate for tigecycline clearance (CL) with a linear relationship. The decision to
include BMI was based on biological plausibility, and the addition resulted in a visual
improvement of the observed and population-predicted concentration goodness-of-ﬁt
plot, as well as the visual predictive check plot (Fig. 2). No signiﬁcant improvement in
the log-likelihood value was observed as a result of adding BMI as a covariate. Although
no obese patients were sampled in this study (BMI range, 22.4 to 26.0), increasing BMI
was found to be associated with increasing CL in the ﬁnal model, and patients were
then categorized into the following two groups for simulation according to BMI values:
normal weight (BMI, 18.5 to 29.9 kg/m2) and obesity (BMI, 30 kg/m2). The simulations
for some of these patients are beyond the BMI of the patients included, and subsequent
dosing recommendations should be considered advisory only.
Monte Carlo simulations. (i) Probability of target attainment (PTA) for the
loading dose.We found that the 100- to 400-mg loading doses of tigecycline achieved
AUC0–24/MIC ratios of 4.5 at MICs of 0.5, 1, and 2 mg/liter on day 1. A loading dose
of 200 or 300 mg leads to a suboptimal tigecycline target value, and the AUC0–24/MIC
ratio is lower than 17.9 at a MIC of 2 mg/liter. Loading doses of 400 mg tigecycline
appear necessary to achieve an AUC0–24/MIC ratio of17.9 at a MIC of 2 mg/liter, while
at a MIC of 0.5 mg/liter, 100 mg is sufﬁcient to achieve an AUC0–24/MIC ratio of 17.9
during the ﬁrst 24 h of treatment (Fig. 3).
(ii) Probability of target attainment for the maintenance dose. Table 3 and Fig.
4 present dosing simulations for various maintenance doses and their relative proba-
bilities of achieving AUC0–24/MIC ratios of 4.5, 6.96, and 17.9 for a range of MICs (0.25
to 8 mg/liter) in patients with normal weight or obesity. These data conﬁrm that obese
patients are associated with reduced PTA, while increases in tigecycline dosing regi-
mens are associated with increased PTA. Among simulated patients achieving a target
AUC0–24/MIC ratio of 6.96, the PTA with a tigecycline dose of 150 mg every 12 h was
96.6% at a MIC of 4 mg/liter in normal-weight patients but 43.1% in obese patients.
When the target was an AUC0–24/MIC ratio of 17.9, PTA of 90%, indicating successful
target attainment, were achieved for normal-weight patients for MICs of 0.5, 1, and 2
mg/liter and corresponding dosing regimens of 50, 100, and 200 mg every 12 h, but
PTA were lower than 60% for obese patients.
(iii) Fractional target attainment. Table 4 shows the fractional target attainment
TABLE 2 Parameter estimates for tigecycline from the ﬁnal covariate two-compartment
population pharmacokinetic model
Parametera Mean SD
Coefﬁcient of
variation (%) Median
V 72.49 21.18 29.22 71.83
CLc 7.50 1.11 14.80 7.73
Kcp 0.31 0.16 51.85 0.28
Kpc 0.29 0.30 104.41 0.18
aCLc, population clearance of tigecycline in the central compartment; V, population volume of distribution in
the central compartment; Kcp, rate constant for tigecycline distribution from the central to the peripheral
compartment; Kpc, rate constant for tigecycline distribution from the peripheral to the central
compartment.
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for simulated PTA for a range of tigecycline doses, patient BMI values, and MIC
distributions (expressed as various AUC0–24/MIC targets) for ﬁve pathogens. These data
show that differences in BMI and different pathogen infections had large effects on
fractional target attainment. In all the obese patients, serum PK/PD targets are rarely
achieved with a dosage of 50 mg every 12 h for A. baumannii, even though the optimal
fractional attainment is achievable for methicillin-resistant Staphylococcus aureus
(MRSA) at the same dosage. A regimen of 100 mg every 12 h is generally required for
A. baumannii at an AUC0–24/MIC target of 6.96, a regimen of 200 mg/12 h for an
AUC0–24/MIC target of 17.9, and no dose adjustment for an AUC0–24/MIC target of 4.5
among normal-weight patients. For obese patients, suboptimal fractional target attain-
ment may still be retained with increasing doses. No dose adjustment is needed for
Enterobacter cloacae, E. coli, K. pneumoniae, or MRSA for an AUC0–24/MIC target of 6.96.
For a therapeutic AUC0–24/MIC target of 17.9, increased dosing needs to be considered,
especially for obese patients, in treating infections with A. baumannii, E. cloacae, E. coli,
or K. pneumoniae.
FIG 1 Diagnostic plot for the ﬁnal population pharmacokinetic covariate model. (Bottom) Observed
tigecycline concentrations versus population-predicted tigecycline concentration. (The r2, bias, and impre-
cision values were 0.733, 0.391 mg/liter, and 4.54 mg2/liter2.) (Top) Observed tigecycline concentrations
versus individual-predicted tigecycline concentration (the r2, bias, and imprecision values were 0.944,
0.0768 mg/liter, and 0.975 mg2/liter2).
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DISCUSSION
Key ﬁndings. The population pharmacokinetic parameters of tigecycline for criti-
cally ill patients were ﬁrst described in this study. We observed that BMI was an
important descriptor of total CL of tigecycline. We also observed that the licensed dose
of tigecycline is sufﬁcient for E. cloacae, E. coli, K. pneumoniae, and MRSA at AUC0–24/
MIC targets of 4.5 and 6.96 in both obese and normal-weight patients. A maintenance
dosing regimen of 200 mg every 12 h is required for A. baumannii at the AUC0–24/MIC
target of 17.9, and 100 mg/12 h at the AUC0–24/MIC target of 6.96 among normal-
weight patients. For obese patients, suboptimal fractional attainment may still be
present despite increasing doses.
Relationship with previous papers. Previously, Van Wart et al. (10) developed a
tigecycline population pharmacokinetic model with patients with cIAI or cSSSI and
FIG 2 Visual predictive check of tigecycline serum data.
FIG 3 Probability of target attainment for various loading doses. Dashed lines represent different
AUC0–24/MIC targets of 4.5, 6.96, and 17.9.
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identiﬁed total body weight, creatinine clearance (CLcr), and male sex as covariates of
CL. Rubino et al. (11) observed an association between tigecycline CL, body surface area
(BSA), and CLcr in community- and hospital-acquired pneumonia. Pai (12) characterized
the concentration proﬁles of tigecycline in the serum and urine of obese class III
(obese-C3) and normal-weight healthy adults. The serum and urine PK of tigecycline are
similar in obese-C3 and normal-weight healthy adults. In the current study, we also
observed an association between tigecycline CL and patient body size—in our case,
BMI. However, the mean tigecycline CL and the volume in the central compartment (Vc)
of 15.7 liters/h and 115 liters from the data of community- and hospital-acquired
pneumonia patients, and 19.2 liters/h and 65.2 liters from patients with cIAI or cSSSI,
were comparable to the mean estimates we found for the present critically ill patient
population. In contrast, the study of Pai et al. found no difference in the mean
parameters of CL and Vc between the obese-C3 and normal-weight healthy adults.
Those authors found that tigecycline clearance in the various populations studied (cIAI,
cSSSI, CAP, and HAP) was associated with patient body size (weight or BSA). In our
study, the patient’s estimated weight was not signiﬁcantly associated with changes in
clearance. All patients received resuscitation ﬂuids as part of standard therapy, but ﬂuid
balance was not found to affect the volume of distribution or clearance. Given the large
volume of distribution of tigecycline, we believe that a relationship between increased
ﬂuid balance and altered volume of distribution is less likely (as with ciproﬂoxacin). The
two subjects who received continuous renal replacement therapy (CRRT) did so prior to
tigecycline treatment. If CRRT was present during the PK sampling, this may have been
an important covariate, and a study of the effect of CRRT on tigecycline clearance is
lacking now and necessary in the future. Importantly, we acknowledge that the sample
size in this study is small, and the lack of inclusion of obese patients (as a consequence
of which we have provided dosing recommendations for patients with characteristics
different from those used in the modeling process) means that studies of critically ill
obese patients are necessary in the future.
TABLE 3 Probabilities of target attainment on day 5 for different BMI groups, target
values, and tigecycline dosage regimensa
Target
Patient
wt
Maintenance
dose (mg/12 h)
PTA for the following MIC (mg/liter):
0.25 0.5 1 2 4 8
AUC0–24/MIC, 4.5 Normal 50 1 1 1 0.973 0.007 0
100 1 1 1 1 0.973 0.007
150 1 1 1 1 0.995 0.594
200 1 1 1 1 1 0.973
Obese 50 1 1 1 0.496 0 0
100 1 1 1 1 0.496 0
150 1 1 1 1 0.986 0.053
200 1 1 1 1 1 0.496
AUC0–24/MIC, 6.96 Normal 50 1 1 0.988 0.344 0 0
100 1 1 1 0.988 0.344 0
150 1 1 1 1 0.966 0.002
200 1 1 1 1 0.988 0.344
Obese 50 1 1 0.974 0 0 0
100 1 1 1 0.974 0 0
150 1 1 1 0.999 0.431 0
200 1 1 1 1 0.974 0
AUC0–24/MIC, 17.9 Normal 50 1 0.974 0.008 0 0 0
100 1 1 0.974 0.008 0 0
150 1 1 0.995 0.617 0 0
200 1 1 1 0.974 0.008 0
Obese 50 1 0.515 0 0 0 0
100 1 1 0.515 0 0 0
150 1 1 0.986 0.056 0 0
200 1 1 1 0.515 0 0
aShading indicates successful target attainment (PTA, 90%). BMI, body mass index; AUC0–24/MIC, ratio of
the 24-h area under the curve to the MIC; PTA, probability of target attainment.
Xie et al. Antimicrobial Agents and Chemotherapy
August 2017 Volume 61 Issue 8 e00345-17 aac.asm.org 6
 o
n
 M
ay 10, 2018 by UQ Library
http://aac.asm
.org/
D
ow
nloaded from
 
We also assessed the attainment of three AUC0–24/MIC targets that have been
derived from different types of infections (17.9 for cSSSI, 6.96 for cIAI, and 4.5 for
pneumonia) according to MIC distributions from EUCAST. The use of the third target
value (4.5) in this analysis was derived from a phase III clinical trial evaluating PK/PD
relationships for efﬁcacy in pneumonia. In that analysis, the ﬁnal multivariable logistic
regression model used the ratio of the free-drug area under the concentration-time
curve from 0 to 24 h (fAUC0–24) to the MIC (fAUC0–24/MIC). The fAUC0–24/MIC break-
point for efﬁcacy was 0.9, but fAUC0–24 was calculated as AUC0–24  fu, where fu is
the fraction of unbound tigecycline, which was assumed to be 0.2 (9). However,
tigecycline shows atypical nonlinear plasma protein-binding behavior, so assuming a
ﬁxed plasma protein-binding value may be problematic, when this value may range
from 71% to 89% (13). Therefore, we used total AUC0–24/MIC targets in this study,
FIG 4 Probability of target attainment from 120 to 144 h for a patient with normal weight or obesity
administered different tigecycline maintenance doses of 50 mg/12 h, 100 mg/12 h, 150 mg/12 h, and 200
mg/12 h. The PK/PD target is achieved when the PTA value is 90% coverage. The targets for which results
are shown are AUC0–24/MIC ratios of 4.5 (A), 6.96 (B), and 17.9 (C).
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although we concede that it would have been preferable to measure unbound con-
centrations.
Concerns about increased mortality associated with tigecycline have led to the
addition of a black box warning to the label by the FDA. The increased risk of death is
believed to be due to therapeutic failure. However, some researchers have proposed
that these therapeutic failures, as well as the rising resistance rates of pathogenic
strains, may be due to tigecycline underdosing (14). A randomized, controlled phase II
trial compared the clinical efﬁcacies of two high doses of tigecycline (150 mg followed
by 75 mg every 12 h and 200 mg followed by 100 mg every 12 h) versus imipenem-
cilastatin (1 g every 8 h) for the treatment of HAP (4). The results revealed no adverse
effects in the high-dose tigecycline patients but a signiﬁcantly increased clinical
cure rate in the 100-mg maintenance dose group (17/20 [85.0%]) relative to those for
the other two groups (16/23 [69.6%] and 18/24 [75.0%]; P  0.05). Another retrospec-
tive study of 54 critically ill patients also described the efﬁcacy and safety of a high-dose
compared with a standard-dose regimen of tigecycline (100 mg every 12 h versus 50
mg every 12 h) in patients with severe infections. Ultimately, all of the patients
tolerated the high doses of tigecycline well, and no adverse reactions were observed
relative to the standard dosing group. The clinical cure rate was signiﬁcantly higher
among patients with ventilator-associated pneumonia on high doses of tigecycline
than in the group on the standard dose (57.5% versus 33.3%; P  0.05) (5). The
simulation results of this study also support the view that in addition to MRSA, other
bacterial infections require higher doses, which appear to be safe, based on existing
literature.
Study limitations. Our study had several limitations. First, the small sample size
may have meant that all clinically relevant covariates could not be sufﬁciently de-
scribed. The likely underestimation of the overall interindividual variability needs to be
TABLE 4 Fractional target attainment across the European Committee on Antimicrobial
Susceptibility Testing MIC distributions for each of the selected pathogensa
Pathogen (n)
Dose
regimen
(mg/12 h)
Probability of target attainment (%) with the
indicated patient wt
AUC0–24/MIC,
>4.5
AUC0–24/MIC,
>6.96
AUC0–24/MIC,
>17.9
Normal Obese Normal Obese Normal Obese
Acinetobacter baumannii (399) 50 95.8 87.1 84.1 77.5 51.9 40.5
100 99.9 98.1 97.3 95.8 77.7 65.7
150 100.0 99.9 99.9 97.8 89.2 78.8
200 100.0 100.0 100.0 99.9 95.8 87.5
Enterobacter cloacae (6,365) 50 98.5 96.7 96.0 94.6 86.8 78.2
100 99.7 99.2 99.0 98.5 94.6 91.1
150 99.9 99.7 99.7 99.1 97.1 94.9
200 100.0 99.8 99.8 99.7 98.5 96.8
Escherichia coli (4,789) 50 99.7 99.5 99.4 99.2 95.3 87.5
100 99.9 99.8 99.8 99.7 99.2 97.5
150 99.9 99.9 99.9 99.8 99.5 99.2
200 99.9 99.9 99.9 99.9 99.7 99.5
Klebsiella pneumoniae (12,530) 50 98.7 96.8 96.0 94.5 85.7 76.1
100 99.9 99.4 99.2 98.7 94.5 90.6
150 99.9 99.9 99.9 99.3 97.2 94.8
200 99.9 99.9 99.9 99.9 98.8 96.9
MRSA (2,426) 50 100.0 99.9 99.8 99.7 99.5 98.2
100 100.0 100.0 100.0 100.0 99.7 99.7
150 100.0 100.0 100.0 100.0 99.9 99.8
200 100.0 100.0 100.0 100.0 100.0 99.9
aA dosing regimen is considered successful if the probability of fractional target attainment is 90%
(boldface values). AUC0–24/MIC, ratio of the 24-h area under the curve to the MIC.
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considered based on the small population. Unfortunately, there were no obese subjects
with PK data available for inclusion in our analysis, and further study on the effect of
obesity on tigecycline PK in the critically ill is still warranted, to further characterize
the effect of BMI on clearance. The latter point is important when one considers that
the associated dosing regimens have been extrapolated from the data used to build the
ﬁnal model. Second, the sample size was not sufﬁcient to measure the impacts of
different drug exposures on clinical outcomes. Finally, we measured concentrations in
plasma, which may not necessarily reﬂect concentrations at the target site, although
the PK/PD targets we used have been demonstrated to be appropriate in previous
studies.
Conclusions. In summary, this study described the ﬁrst population pharmacokinet-
ics of tigecycline in critically ill patients. Increases in tigecycline doses appear to be
necessary for Gram-negative pathogens in these patients. Increasing BMI is associated
with increasing CL of tigecycline and necessitates higher doses. Further clinical studies
of tigecycline are still warranted to determine the effect of optimized dosing on clinical
outcome, and these proposed dosing regimens need to be validated by a larger PK
study, because we included simulations of BMI that exceeded the range used in the
model-building process. However, in the absence of any data, ours is useful as an initial
guide to assist clinicians.
MATERIALS AND METHODS
Setting. This was a prospective study performed in a tertiary intensive care unit (ICU). The study was
conducted according to the Declaration of Helsinki and was approved by institutional review boards of
the First Afﬁliated Hospital of Xi’an Jiaotong University. Written informed consent to participate was
obtained from all patients after they had been given detailed information about the study. If a subject
was unable to provide legally effective consent, written informed consent was obtained from a close
relative.
Study population and protocol. The criteria for patient inclusion were as follows: critically ill
hospitalized males or nonpregnant females aged 18 years with severe infections which the treating
clinician was treating with tigecycline. All patients enrolled in the study were given an intermittent
intravenous 100-mg loading dose of tigecycline, followed by 50 mg every 12 h for at least 5 days. Venous
blood samples (1 ml) were collected before the seventh dose of tigecycline (time point 0; presumed
pharmacokinetic steady state) and at 0.5, 1, 2, 3, 4, 6, 8, and 12 h after that dose. All antimicrobial
prescription and routine examination data are available from the hospital electronic information systems.
All the patient body weights were recorded on admission to the ICU; they were obtained from recent
health records, parental knowledge, or direct measurement. Safety and adverse events were determined
through the biochemical abnormalities documented in medical records.
Blood sample handling, storage, and assay. The blood samples were collected into Vacutainer
tubes (Becton Dickinson, Franklin Lakes, NJ, USA) and were immediately centrifuged at 3,500 rpm for 5
min; the resultant supernatants were stored frozen at 80°C until analysis. The serum tigecycline
concentrations of blood samples were measured by an established liquid chromatography–tandem mass
spectrometry method (15). The assay was linear over the concentration range of 0.005 to 2 mg/liter. The
mean recovery ranged from 94.3% to 105.6%, and the matrix effect ranged from 92.1% to 97.6%.
Population pharmacokinetic modeling. One- and two-compartment models were ﬁtted with the
nonparametric adaptive grid (NPAG) algorithm by the Pmetrics package for R (Laboratory of Applied
Pharmacokinetics and Bioinformatics, Children’s Hospital Los Angeles, University of Southern California,
Los Angeles, CA, USA) (16). Biologically plausible demographic and clinical characteristics were tested as
covariates for model inclusion. Data, including age, sex, height, total body weight, body mass index (BMI),
body surface area, serum creatinine concentration, estimated clearance of creatinine (CLcr), albumin
concentrations, and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (17), were
tested by plotting with the pharmacokinetic parameter estimates to assess correlation. Covariates were
included in the model if they signiﬁcantly improved the log likelihood (P  0.05) and/or improved the
goodness-of-ﬁt plots.
Model diagnostics. The goodness of ﬁt was assessed by visual inspection of the population
observed-predicted and individual observed-predicted concentration scatter plots, coefﬁcient of deter-
mination of linear regression, and log-likelihood values from each run. Predictive performance was
evaluated based on mean prediction error (bias) and the mean bias-adjusted squared prediction error
(imprecision) of the population and individual prediction models in the central compartment.
The suitability of the ﬁnal covariate model was evaluated by a visual predictive check using 1,000
simulations.
Probability of target attainment. Monte Carlo simulations (n  1,000) were employed using
Pmetrics to determine the probability of target attainment (PTA) for AUC0–24/MIC targets of 4.5, 6.96, and
17.9 for various MICs (0.25 to 8 mg/liter) in patients with normal weight (BMI, 18.5 to 29.9 kg/m2) or
obesity (BMI, 30 kg/m2).
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Fixed intravenous tigecycline loading doses of 100 mg, 200 mg, 300 mg, and 400 mg (0.5-h infusion)
were simulated from 0 to 12 h. Simulated AUC0–24/MIC values were compared with PK/PD targets of 4.5,
6.96, and 17.9. Maintenance doses of 50 mg/12 h, 100 mg/12 h, 150 mg/12 h, and 200 mg/12 h from 120
to 144 h were also simulated for the three PK/PD targets.
Fractional target attainment calculation. MIC data for Acinetobacter baumannii (n  399), Entero-
bacter cloacae (n  6,365), Escherichia coli (n  4,789), Klebsiella pneumoniae (n  12,530), and
methicillin-resistant Staphylococcus aureus (MRSA) (n  2,426) strains from the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) database were used to determine fractional target attain-
ment (http://www.eucast.org; last accessed, 31 October 2016). Fractional target attainment was deﬁned
as the expected population PTA for tigecycline against a MIC distribution. A priori, a dosing regimen was
considered successful if the fractional target attainment was 90%.
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